User: Genecampaign Topic: IP
Category: drugs :: everywhere
Last updated: Mar 16 2019 16:18 IST RSS 2.0
 
1 to 20 of 4,467    
Can Biotechnology be Indian economy's next success story? 16.3.2019 Sify Finance
The information technology industry has provided stellar growth for Indian economy, but as dividends reach an inflection point, here's what biotechnology sector could offer.
Also found in: [+]
Dr Reddy's re-launch generic version of Suboxone in US 21.2.2019 Sify Finance
With US Supreme Court ruling in its favour, Indian pharma major Dr. Reddy's Laboratories on Wednesday announced re-launch of generic version of Suboxone, a sublingual film for opioid addition treatment, in the US market.
Also found in: [+]
Make India the international capital for Generic Medicines: Vice President 21.12.2018 Govt of india: PIB
The Vice President of India, Shri M. Venkaiah Naidu has called up on the pharmaceutical industry to work towards making India an International Capital of Generic Medicines.  Addressing the 70th Indian Pharmaceutical Congress at Amity University, Noida today, Shri Naidu said that India becoming the largest provider of generic drugs globally with the Indian generics accounting for 20 % of global exports in terms of volume was an eloquent testimony to the competence of the Indian pharma sector in terms of quality and pricing.
Also found in: [+]
Innovation is for the betterment of mankind: Vice President 18.11.2018 Govt of india: PIB
The Vice President of India, Shri M. Venkaiah Naidu has said that Innovation is for the betterment of mankind and India is encouraging the spirit of innovation among the educated enterprising youth. He was addressing the gathering after inaugurating the International Conference ‘Asian Patent Attorneys Association’, here today.
Also found in: [+]
J & J's loss may be good news for Indian pharmas 1.11.2018 Rediff: Business
Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga
Also found in: [+]
'This movie has made China introspect and learn from India' 21.7.2018 Rediff: Columns
Dying To Survive, on its way to becoming China's biggest box office hit, may compel the Xi Jinping government to change its policy towards Indian pharmaceutical companies, says Tarun Vijay.
Also found in: [+]
Will this movie change China's drug policy towards India? 14.7.2018 Rediff: News
Dying To Survive, on its way to becoming China's biggest box office hit, may compel the Xi Jinping government to change its policy towards Indian pharmaceutical companies, says Tarun Vijay.
Also found in: [+]
Apple patents BP monitoring 'cuff' 8.6.2018 Sify Finance
Apple has patented a design for a wearable blood pressure monitor -- a cuff, equipped with a sensor that is expected to be Bluetooth compatible and sport a touchscreen.
Also found in: [+]
CSIR bags the Clarivate Analytics India Innovation Award 2018 in the Government Research Organizations Category 24.5.2018 Govt of india: PIB
Council of Scientific & Industrial Research has been awarded the Clarivate Analytics India Innovation Award 2018 in the Government Research Organizations Category. This award yet again recognizes CSIR as the top innovator.
Also found in: [+]
Ayushman Bharat may help patients access life-saving drugs 16.5.2018 Rediff: Top Stories (India)
'We have often heard the mythical argument that patents block access to life-saving drugs, but only 5% of medicines from multinational companies are under patent protection in India.''Where these patented products are beyond the reach of Indian patients, the companies have programmes to facilitate access to their drugs, for free or for a fraction of the price,' points out Ranjana Smetacek, former director general, Organisation of Pharmaceutical Producers of India.
Also found in: [+]
Prices of key diabetes, cancer drugs may drop by 25% 8.3.2018 Rediff: Business
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments.
Also found in: [+]
David vs Goliath: How Wockhardt plans to beat global challenge 22.1.2018 Rediff: Interviews
Only 11 antibiotics in clinical trials have received qualified infectious disease product status from the US FDA, of which five are Wockhardt's drugs.
Also found in: [+]
Indian pharma growth likely to be moderate: ICRA 3.1.2018 Sify Finance
[India], Jan 3 (ANI): The growth trajectory for Indian pharmaceutical industry is likely to be moderate, according to credit rating agency ICRA.
Also found in: [+]
Succession doubts cloud Apotex future after billionaire owner's death 22.12.2017 Sify Finance
By Matt Scuffham
Also found in: [+]
Morepen Gets US FDA clearance for its Bulk Drug Montelukast Sodium 20.12.2017 Sify Finance
[India], Dec 20 (ANI-NewsVoir): The United States Food and Drug Administration (USFDA) has cleared Montelukast Sodium, a bulk drug / API manufactured by Morepen Laboratories Ltd., for sale in the
Also found in: [+]
BRIEF-India's Lincoln Pharmaceuticals Gets Patent For 'Antimalarial Drug' 19.12.2017 Sify Finance
Dec 19 (Reuters) - Lincoln Pharmaceuticals Ltd:
Also found in: [+]
After 15 years, Ranjit Shahani steps down as Novartis MD 14.11.2017 Rediff: Business
The face of MNC drug firms in India and champion of IPR protection, he oversaw the Swiss giant's India expansion, its forays into new therapies and setting up of its global service centre in Hyderabad
Also found in: [+]
Base Erosion and Profit Shifting guidelines stump MNCs 14.10.2017 ET: Pharma
Under BEPS, multinationals will be required to declare details of revenues earned, taxes paid, employees hired, supply chain management in every country they operate in.
Also found in: [+]
Activists challenge Pneumonia vaccine patent in Delhi High Court 14.10.2017 DNA: Mumbai
Activists have challenged the patent claims of pharma giant Pfizer on a vaccine for pneumonia in the Delhi High Court. Médecins Sans Frontières or Doctors Without Borders (India) has filed a petition to overturn the patent granted earlier this year, on August 13 by the Indian Patent Office to Pfizer. “India has dashed hopes for improved access to an affordable PCV13 when it granted a patent to Pfizer for its PCV 13 product, marketed as Prevnar13, which will expire only in 2026,” a statement issued by MSF said. In the petition, MSF argues that in August 2017, the Delhi Patent Office erroneously granted a patent to Pfizer by disregarding the evidence MSF produced indicating that the pharmaceutical giant’s claim to a patent was spurious. MSF argued that the mere addition of serotypes to the already established 7-valent vaccine did not involve a technical advancement – it was merely a tactic to preserve Pfizer’s monopoly for many more years. The decision also has broader implications, as it indicates a ...
Also found in: [+]
MSF drags govt to Delhi HC over Pfizer's pneumonia vaccine patent 14.10.2017 ET: Pharma
The Indian patent office granted Pfizer a patent for its vaccine PCV13 (13-valent pneumococcal conjugate vaccine), sold here under the brand ‘Prevenar13’ for over 10 years.
Also found in: [+]
1 to 20 of 4,467